Oral Revalida: Emergencies
Oral Revalida: Emergencies
Oral Revalida: Emergencies
REVALIDA
EMERGENCIES
2016-2017
“Ars longa, vita brevis, occasio praeceps, experimentum periculosum, iudicium difficile.”
-Hippocrates
JMFV D2017, UST-FMS
UST-FMS Oral Revalida
Topics for Medical & Surgical Emergencies 2017
1. Basic Life Support p3
2. Acute Upper Airway Obstruction p100 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis,
Management)
3. Acute Asthma in Exacerbation p42 (Definition, Pathogenesis, Precipitating Factors, Clinical Manifestations,
Management)
4. Respiratory Distress Syndrome p77 (Definition, Incidence, Risk Factors, Pathophysiology, Clinical Manifestations,
Diagnosis, Prevention, Management, Prognosis)
5. Anaphylaxis p65 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management, Prevention)
6. Intestinal Obstruction in Children p97 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis,
Management)
th
7. Diarrhea & Dehydration 5 ed p52 (Definition, Etiopathogenesis, Clinical Manifestations, Evaluation of
dehydration, Management)
8. Shock p21 (Definition, Types, Etiopathogenesis, Clinical Manifestations, Management)
9. Acute Abdomen p111 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management – at least 2
GI cases)
10. Acute Cholangitis p116 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
11. Gastrointestinal Bleeding p302 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
th
12. Porto-systemic encephalopathy 5 ed p100 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis,
Management, Complications)
th
13. Hypertensive Crisis 5 ed p144 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
14. Acute Heart Failure p123 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
15. Acute Myocardial Infarction p221 (Definition, Etiopathogenesis and types, Clinical Manifestations, Diagnosis,
Management)
16. Pulmonary Embolism p212 (Definition, Etiopathogenesis, Risk factors, Clinical Manifestations, Diagnosis,
Management)
17. Severe Asthma p208 (Definition, Etiopathogenesis, Clinical Manifestations, Management)
18. Hemoptysis p169 (Definition/classification, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
19. Pneumothorax p176 (Definition/classification, Risk factors Etiopathogenesis, Clinical Manifestations, Diagnosis,
Management)
20. Acute Respiratory Failure p133 (Definition/types, Etiopathogenesis, Clinical Manifestations, Diagnosis,
Management)
21. Adrenal Crisis p115 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
22. DKA p158 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis/tests, Management, monitoring)
23. Thyroid Storm p163(Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis/tests, Management)
24. Uremia p192 (Definition, Etiopathogenesis, Clinical Manifestations, Procedures, Management)
th
25. Rabies 5 ed p313 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
th
26. Tetanus 5 ed (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
27. Increased ICP p237 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
28. Stroke p240 (Definition, Risk factors, Management)
29. Status Epilepticus p245 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
30. Spinal Cord Compression p248 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
31. Vaginal Bleeding in Pregnancy p269 (Causes, diagnosis, management)
32. Hypertension in Pregnancy p277 (Manifestations, diagnosis, management)
33. Gynecologic Emergencies p284 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management –
at least 2 emergencies)
34. Head Trauma p307 (Classification, Evaluation, Management)
35. Maxillofacial Injury p336 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management
according to site of injury)
36. Mechanical Intestinal Obstruction p345 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis,
Management for 1 type)
37. Spine Trauma p313 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
38. Thermal Burns p370/339 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
th
39. Fractures 5 ed p229 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
40. Acute Urinary Retention p298 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
41. Ocular Trauma p402 (Causes, Clinical Manifestations, Management)
42. Foreign body in the esophagus/airway p441 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis,
Management)
43. Appendicitis p293 (Definition, Etiopathogenesis, Clinical Manifestations, Diagnosis, Management)
1. Basic Life Support: Cardiorespiratory Resuscitation p3
Basic Life Support is the foundation for saving lives following sudden cardiac arrest which continues to be a
leading cause of death in many parts of the world. Considering its multiple etiologies, the variety of
circumstances where it could occur & that it can happen to anyone - a universal strategy for successful
resuscitation is needed. The actions comprising this strategy are called the links in the “Chain of Survival”
which include:
I. Immediate recognition of cardiac arrest & activation of the Emergency Response System (EMS)
II. Early Cardiopulmonary Resuscitation (CPR)
III. Rapid defibrillation
IV. Effective Advanced Life Support (ALS)
V. Integrated post-cardiac arrest care
I. Immediate recognition of cardiac arrest & activation of the EMS.
• An adult is found unconscious, unresponsive or witnessed to have collapsed. Survey the scene &
ensure that it is safe
• Perform primary survey: Check for response by tapping on the shoulder and shouting,
“Hey, hey, are you okay?” x2 à No response
• “Activate the EMS and somebody get me an AED!”
II. Early CPR
• ABC à CAB
o Formerly sequenced as Airway-Breathing-Circulation or ABC, a change in the 2010 American
Heart Association Guidelines recommends the initiation of chest compressions before
ventilations thus the new sequence is CAB
o Chest compressions will be initiated sooner
o Critical initial elements of CPR are chest compressions and early defibrillation
• Extend the head to expose the neck. Take <10 seconds to feel for the pulse à No pulse à start CPR
• Compression
o Forceful rhythmic applications of pressure on the chest which create blood flow by increasing
intrathoracic pressure and directly compressing the heart which then generates blood flow and
oxygen delivery to the myocardium and brain
o “I will place the heel of one hand over the heel of the other on the patient’s sternal notch, then I
will position my shoulders over hands with elbows locked and arms straight”
o “I will then deliver High Quality chest compressions by
§ Pushing hard & fast delivering 100 compressions/min with a depth of at least 2in/5cm
and
§ I will Allow complete recoil of the chest after each compression to allow the heart to fill
completely”
• Airway
o “I will then start rescue breaths by mouth-to-mouth or bag-mask to provide oxygenation and
ventilation”
o “I will then open the airway by performing head tilt/chin lift maneuver or jaw thrust for
suspected victims of cervical spine injury (this is when the jaw is lifted without tilting the head)”
o Check if patient is breathing → look at chest, listen/feel breaths of the patient
o If still breathless for 10 seconds, then you have to “BREATHE” for the patient
• Breathing
o “I will deliver 2 rescue breaths, each breath over a full second and ensure it is sufficient to
produce visible chest rise”
o “I will adhere to a compression to ventilation ratio of 30 chest compressions to 2 ventilations
for 5 cycles”
o “If the patient has an advanced airway (Endotracheal tube, LMA), I will give 1 breath every 6 to
8 seconds and there should be no pause in compressions or ventilations”
JMFV D2017, UST-FMS
III. Rapid defibrillation
• Attach the AED, turn it on, follow the prompts, resume chest compressions after shock
• Shockable rhythms
o VF (ventricular fibrillation – completely erratic rhythm w/ no identifiable waves) OR
o Pulseless VT (ventricular tachycardia - also known as VF) – rhythm >100 or 120 beats/min with ≥
3 irregular beats in a row, arising distal to the bundle of His
IV. Effective advanced life support
V. Integrated post-cardiac arrest care
Assess Hydration Status: IMCI Guidelines
JMFV D2017, UST-FMS
Plan A: Treat Diarrhea at Home
• Indications
o Children with no dehydration
o Improved status after Plan B or C
o Children that cannot be returned to the health worker if diarrhea gets worse
• Goals
o Treat child’s current episode of diarrhea at home
o Give early treatment for future episodes of diarrhea
• 4 rules for treating diarrhea at home
1. Give the child more fluids than usual to prevent dehydration
§ Give ORS, if not possible – water. Give as much as the child will take, continue until
diarrhea stops (replace volume per volume)
§ Instructions: Dissolve 1 packet of ORS solution in 200 ml of water and give as follows:
2. Give Zinc supplementation
§ <6 months – 10 mg QD x 14 days
§ >6 months – 5 years old – 20 mg QD x 14 days
3. Give the child plenty of food to prevent under nutrition
§ Continue to breastfeed frequently, if not breastfed, give usual milk
§ If < 6 months old and not yet taking solid food, dilute milk formula with equal amount of
water for 2 days
§ If > 6 months or already taking solid food,
• Give cereal or other starchy food mixed with vegetables, meat, or fish. Add 1 to 2
teaspoonfuls of vegetable oil to each serving
• Give fresh fruit juice or mashed bananas to provide Potassium
• Give freshly prepared food. Cook and mash or grind food well
• Encourage child to eat, offer at least 6 times daily
• Give same foods after diarrhea stops, give extra meal each day for 2 weeks
4. Take child to health worker if child does not get better in 3 days or develops any of the
following:
§ Many watery stools
§ Repeated vomiting
§ Marked thirst
§ Eating or drinking poorly
§ Fever
§ Blood in stool
Plan B: Treat Some Dehydration with ORS
• Approximate the amount of ORS to be given over a 4-hour period
o Weight unknown:
o Weight known:
§ Weight in kg x 75 = ORS in ml
o If the child wants more ORS, give more. Encourage mother to continue breastfeeding
o For infants < 6 months who are not breast fed, also give 100 – 200 ml clean water during this
period
• Observe the child carefully and help the mother give ORS
o For under 2 years, give teaspoonful every 1 to 2 minutesFor older, give frequent sips from a cup
o If child vomits, wait for 10 minutes then give solution more slowly thereafter
o If the child’s eyelids become puffy, stop ORS and give plain water or breast milk then give ORS
according to plan A when puffiness is gone
• Reassess after 4hours of initial hydration
o No signs of dehydration à (+) Urine output, child falls asleep à Plan A
o Signs of dehydration à Repeat Plan B but offer food, milk, juice as in Plan A
o Signs of severe dehydration à Plan C
• If mother must leave before completing Plan B
o Instruct how much ORS to finish in 4-hour treatment. Give ORS packets enough for rehydration
and 2 days
JMFV D2017, UST-FMS
Plan C: Treat Severe Dehydration Quickly
•If possible, observe the patient at least 6 hours after rehydration to be sure mother can maintain
hydration giving ORS by mouth
• If patient is > 2 years old and there is cholera in your area, give appropriate oral antibiotic when patient
is alert
Management of Associated Problems
• Dysentery – blood in the stool
o Treat for 5 days with an oral antibiotic recommended for Shigella in your area: Trimethoprim
(TMP) + Sulfamethoxazole (SMX)
§ Children: TMP 5 mg/kg + SMX 25 mg/kg BID for 5 days
§ Adults: TMP 160 mg + SMX 800 mg BID for 5 days
o Teach the mother to treat the child as described in Plan A
o See the child again after 2 days if:
§ < 1 years old, initially dehydrated, there is still blood in the stool, no improvement
o If the stools is still bloody after 2 days change oral antibiotic to alternative recommended for
Shigella in your area
§ Nalidixic Acid
• Children: 15 mg/kg QID for 5 days
• Adults: 1
g TID for
5 days
§ Ampicillin:
Children: 25
mg/kg QID
• Persistent Diarrhea (>14 days)
o Refer to a hospital
• Severe under nutrition
o Do not attempt
rehydration
o Refer to hospital for
management
o Give ORS 5 mL/kg/hr
• Fever
o Give Paracetamol q4 for Temperature 39.0°C or greater
o If there is Falciparum malaria in the area, and child has fever of 38.0°C and above OR history of
fever in the past 5 days: Give antimalarial
JMFV D2017, UST-FMS
9. Acute Abdomen p.111
Definition
• Acute abdomen is a condition where the patient experiences moderate to severe abdominal pain of
less than 24h duration
• Has many causes and only after a thorough history taking and complete PE aided by laboratory and
radiologic examination, can a physician differentiate those conditions needing surgical vs medical
management
Pathogenesis
• Depends on the particular disease entity but abdominal pain is divided into 3 neuroanatomic
categories: visceral, parietal, and referred.
Visceral Pain Somatic Pain Referred Pain
Pain transmission Unmyelinated C fibers Myelinated A-δ fibers Interplay b/w 2 fibers
Character Dull crampy, gnawing, Sharp, sudden, well- Felt in areas remote
midline, difficult to localized pain from the diseased organ
localize
Mechanism Obstruction, ischemia, or Irritation of myelinated Visceral and somatic
inflammation can cause fibers that innervate the afferent neurons from a
stretching of unmy- parietal peritoneum, different anatomic
elinated fibers that usually the portion region converge on 2nd-
innervate the walls or cover- ing the anterior order neurons on the
capsules of organs abdominal wall spinal cord at the same
spinal segment
JMFV D2017, UST-FMS
10. Acute Cholangitis p116
Definition/Pathogenesis
• Bacterial infection superimposed on an obstruction of the biliary tree
• 2 factors are necessary for cholangitis to occur:
o Biliary obstruction
o Bactobilia
• Biliary obstruction causes an increase in intrabiliary pressure, bile stasis, diminished biliary secretion &
cholangiovenous reflux à this leads to increased permeability of bile ductules, permitting
translocation of bacteria and toxins from the portal circulation into the biliary tract
• Bacteria gain access into the biliary tree via
o Ascending route (duodenobilious reflux)
o Descending route (hematogeneous spread)
• Patients usually manifest with the Charcot’s Triad of RUQ Pain, Fever & Jaundice
• In its severe form – Acute suppurative cholangitis, pus is present under pressure in the bile ducts which
can lead to a rapid spread of bacteria via the liver into the blood causing septicemia. Patients usually
manifest with Reynold’s Pentad: Charcot’s Triad + Hypotension + Altered Sensorium
Etiology
• Forms of obstruction
o Gallstones impacted in the CBD – 85% of cases
o Bile duct strictures
o Obstructing Neoplasms – ampullary cancer, pancreatic cancer, cholangiocarcinoma
o Parasitic infections – Ascaris lumbricoides, Chlonorchis sinensis
o Congenital abnormalities of the BD – choledochal cysts, Caroli’s disease
• Bacteria most commonly cultured in these cases include
o Enteric gram negative & positive organisms
§ E. coli
§ Enterococci
§ Klebsiella
§ Pseudomonas
§ Proteus
o Anaerobic organisms
§ Bacteroides fragilis
§ Clostridium perfringens
o Usually polymicrobial
Clinical Manifestations
• Charcot’s Triad
o RUQ Pain, Fever, Jaundice
o Full triad is present in only 70% of the cases
• Reynold’s Pentad
o RUQ Pain, Fever, Jaundice + Hypotension, Mental confusion
o Denotes severe cholangitis/Acute Suppurative Cholangitis
o Associated with a high mortality rate & requires urgent biliary drainage
Laboratory/Ancillary Procedures
• Leukocytosis with immature neutrophil forms
• Elevated serum bilirubin & Alkaline phosphatase
• Elevated AST & ALT
• Blood culture often reveals infecting organisms
• PT may be deranged specially in patients with long-standing biliary obstruction
• LGBPS – initial imaging modality that should be done
o Can detect the cause of obstruction
o Has a low sensitivity in detecting a CBD stone itself, it may show evidence of obstruction such as
biliary ductal dilatation
• ERCP
o Endoscopic Retrograde Cholangiopancreatography
o Diagnostic as well as Therapeutic modality
o Can demonstrate bile duct stones, strictures & congenital anomalies
o Tissue sample for biopsy or brush cytology can also be obtained in cases of malignant causes of
biliary obstruction
• MRCP & EUS
JMFV D2017, UST-FMS
o Magnetic Resonance Cholangiopancreatography
o Endoscopic Ultrasonography
o Techniques to evaluate the bile duct & its surrounding structures
o Have a role in the diagnosis but are not necessary in patients with acute cholangitis
Management
• NPO for organ rest
• IV Fluids to cover for 3rd space losses
• IV Antibiotics STAT
o Ampicillin + Aminoglycoside or 3G Cephalosporin
§ Ampicillin + Gentamycin – pregnant patient
§ Cefoxitin 2g/IV q6-8h – initially, usually sufficient
§ Piperacillin- tazobactam 3.375g/IV q6h – more severe cases
§ Meropenem 1g/IV q8h - if resistant organisms are suspected
o Flouroquinolones – high biliary excretion, also a good choice
o Metronidazole – usually added to cover anaerobes
• Biliary decompression via ERCP
o If antibiotics offer no response
o Mainstay of treatment of acute cholangitis
o If adequate, a 3-day regimen of antibiotics will be sufficient
• Sphincterotomy + Stone extraction – done for CBD stones
• Biliary stenting – effective in cases of bile duct strictures
• Nasobiliary drain or Biliary stent – initially placed in severely sick patients & those with coagulation
problems, once stable ERCP or surgery can be performed
• Biliary drainage via Percutaneous Transhepatic Biliary Drainage/Surgery – if ERCP is unsuccessful
JMFV D2017, UST-FMS
12. Porto-systemic Encephalopathy p.703 CMDT 2017
Definition
• Hepatic encephalopathy is a complication of liver cirrhosis which is a state of disordered CNS function
resulting from the inability of the liver to adequately detoxify noxious agents of gut origin, this inability
of the liver to detoxify is secondary to hepatocellular dysfunction and portosystemic shunting caused
by either an underlying chronic hepatic pathology or acute hepatic failure, after exclusion of brain
disease
o Acute liver failure/chronic liver disease à hepatocellular dysfunction or portosystemic shunting
à inability of the liver to adequately detoxify noxious agents of gut origin à disordered CNS
function
• In the setting of acute hepatic failure, it is a syndrome characterized by psychiatric as well as
neurologic abnormalities with jaundice manifesting within 2 to 8 weeks from the onset of symptoms in
the absence of any pre-existing liver disease
Etiology
• Viruses such as Hepatitis
• Chemicals such as Ammonia
• Drugs such as opioids and sedatives
• Gastrointestinal bleeding (Bleeding into the intestinal tract may significantly increase the amount of
protein in the bowelàmore amino acids à more ammonia)
• Surgery, cancer, and radiation
• In the presence of chronic liver disease, precipitating factors include azotemia, hypokalemia, high
protein diet, gastrointestinal bleeding, and hypovolemia
• Other precipitants: Constipation, alkalosis, and potassium deficiency induced by diuretics, opioids,
hypnotics, and sedatives; medications containing ammonium or amino compounds; paracentesis with
consequent hypovolemia; hepatic or systemic infection; and portosystemic shunts (including TIPS)
Pathophysiology
• Normally
o Ammonia is metabolized from dietary amino acids by resident bacterial flora in the colon.
o The ammonia is reabsorbed by the portosystemic circulation.
o 80-90% of the total ammonia produced is shunted to the liver where it is detoxified into urea
and eventually excreted in urine.
o The remaining 10-20% is shunted to the other ammonia metabolizing organs: the brain, heart,
and kidneys
• When more than 60% of hepatic function is lost or when portosystemic shunting towards the brain,
heart, and kidneys is present, there is failure of ammonia detoxification.
• As ammonia levels rise, the brain, heart, and kidneys attempt to compensate but eventually become
overloaded and fail to metabolize the overwhelming amount of ammonia, thus hyperammonemia
occurs
• Ammonia exerts multiple neurotoxic effects resulting to neurologic and psychiatric abnormalities.
Types
• Type A – associated with Acute Liver Failure
• Type B – associated with porto-systemic Bypass & no intrinsic liver disease
• Type C – associated with Cirrhosis and portal hypertension or portal-systemic shunts
Clinical Manifestations
• The major clinical features of hepatic encephalopathy include: altered mental status, personality
changes, neuro-ophthalmologic changes, motor abnormalities, and electroencephalographic findings.
• Based on these clinical features, hepatic encephalopathy may be classified to indicate the severity of
the disease.
o Grade 1 - normal EEG finding as well as the motor abnormality being tremors only. Symptoms
include a sleep reversal pattern, emotional lability, irritability, and mild confusion
o Grade 2 - and the succeeding stages are characterized by abnormal EEG findings which reveal
slow, high amplitude, triphasic waves, as well as the presence of asterixis. Symptoms include
lethargy, inappropriate behavior, and disorientation
o Grade 3 – somnolence, aggressive behavior, and severe confusion
o Grade 4 - may reveal a comatose patient with or without response to normal stimuli
JMFV D2017, UST-FMS
Diagnosis
• Diagnosis is based primarily on detection of characteristic symptoms and signs, including asterixis
Management
Since the main pathology in hepatic encephalopathy is the elevation of ammonia levels treatment is geared
towards reducing ammonia formation
• Lactulose
o Mainstay of treatment in hepatic encephalopathy; A non-absorbable synthetic disaccharide
syrup
o Digested by bacteria in the colon to short-chain fatty acids, resulting in acidification of colon
contents
§ This acidification favors the conversion of ammonia (NH3) to ammonium ion (NH4)
§ NH4 is not absorbable & easily excreted in the urine, whereas NH3 is absorbable and
thought to be neurotoxic.
o Also induces catharsis which promotes turnover of gut flora, decreasing the number of
ammonia forming flora
o 30 ml PO TID to QID and is titrated to achieve 3 to 5 soft stools per day
o Continued use of lactulose after an episode of acute encephalopathy reduces the frequency of
recurrences.
• Metronidazole & Neomycin
o Antibiotics traditionally used to increase turnover of gut ammonia-producing intestinal flora
o Neomycin: Aminoglycoside which interferes with bacterial protein synthesis by binding to the
30S ribosomal subunit
o Metronidazole 250mg PO TID: inhibits nucleic acid synthesis by disrupting DNA
o Poor safety profile due to poor safety profile: Neomycin causes ototoxicity and nephrotoxicity
while Metronidazole causes peripheral neuropathy
• Rifamixin
o Derivative of Rifampicin, which binds to the beta subunit of bacterial RNA polymerase to
disrupt DNA formation, has been used for its better safety profile
o Antibiotic given in order to promote turnover of ammonia-producing intestinal flora
o 550mg PO BID
• Dietary protein restriction (60-80 g/day as tolerated)
o No longer advised as a standard of care in hepatic encephalopathy as the ensuing malnutrition
has been found to outweigh any beneficial effects
o Reserved for the small subset of patients who completely are unable to tolerate protein and
often trial of shifting to vegetable sources for protein is attempted before complete restriction
of protein in the diet.
• Diet with Branched Chain Amino Acids
o Leucine, valine and isoleucine
o BCAAs supply the TCA-cycle with carbon skeletons and thereby enhance the procuction of alfa-
ketoglutarate (α-KG)
o α-KG can be reductively aminated to glutamate (Glu) and glutamate may be amidated to
glutamine (Gln)
§ BCAA à aKG à Glutamate
§ Glutamate + Free NH4 à Glutamine (Reaction is catalyzed by Glutamine Synthetase
which present in large amounts in skeletal muscle)
o This way, you contain the ammonia in Glutamine
• Correct the underlying triggers
o Dehydration, GI Bleeding, electrolyte imbalances (Repletion of K) etc
JMFV D2017, UST-FMS
13. Hypertensive Crisis p.144, JNC 7, JNC 8, CMDT 2017
Definition
• Hypertensive crisis is a sudden, acute blood pressure elevation to levels higher than what is normal for
the affected individual
• 2 Types
o Hypertensive Urgency
o Hypertensive Emergency
• Hypertensive Urgency
o JNC 7: Situations associated with severe elevations in BP without progressive target organ
dysfunction.
o CMDT 2017: These include patients with asymptomatic severe hypertension that persists after
a period of observation which requires BP reduction (not necessarily to normal) within a few to
24 hours using Oral medications
• Hypertensive Emergency
o JNC 7: A severe elevation in blood pressure (usually >180/120 mm Hg) complicated by evidence
of impending or progressive target organ dysfunction. Hypertensive emergency is a clinical
diagnosis and the clinical state of the patient is more important than the absolute value of the
BP
o This requires immediate (within 1 hour) BP reduction (not necessarily to normal) to prevent or
limit target organ damage using parenteral agents
o Clinical manifestations of target organ damage usually involve derangements in the neurologic,
cardiac, or renal systems
§ Myocardium – most common target organ with a manifestation of ACS (Unstable angina
or MI)
§ Hypertensive Encephalopathy – headache, irritability, confusion, and altered mental
status due to cerebrovascular spasm
§ Hypertensive Nephropathy – hematuria, proteinuria, and acute kidney injury due to
arteriolar necrosis and intimal hyperplasia of the interlobular arteries
§ Others include, but not limited to: acute hemorrhagic or ischemic stroke, acute
papilledema, acute pulmonary edema, aortic dissection and eclampsia
o Types:
§ Accelerated hypertension - characterized by headaches, blurred vision, and focal
neurologic deficits
§ Malignant hypertension - Accelerated hypertension with papilledema, Encephalopathy
or nephropathy accompanying hypertensive retinopathy has historically been termed
malignant hypertension
JNC 7 Blood Pressure Classification (AV Chrobanian et al: JAMA 289: 2560, 2003)
Classification Systolic Diastolic NB
(mmHg) (mmHg)
Normal <120 and <80 J
Pre-hypertension 120-139 or 80-89 Not a disease category
Stage 1 140-159 or 90-99
Hypertension On 2 or more readings on at least 2
different visits one to several weeks apart
Stage 2 >160 or >100
Hypertension
Hypertensive BP elevation with NO evidence of end
Urgency >180 or >120 organ damage
Hypertensive BP elevation WITH evidence of end organ
Emergency damage
Etiology
• Consequence of uncontrolled longstanding primary or essential hypertension – 90% of cases
• Stimulant intoxication, including cocaine, methamphetamine, and phencyclidine as well as withdrawal
syndromes from the anti-hypertensives such as clonidine and beta blockers
• Uncontrolled causes of secondary hypertension such as renal parenchymal disease, renovascular
disease, pheochromocytoma, Cushing’s syndrome, Primary Hyperaldosteronism, Coarctation of the
aorta, and obstructive sleep apnea, adverse drug interactions with monoamine oxidase inhibitors
(MAO-I)
JMFV D2017, UST-FMS
Management
• Anticoagulants
o Main treatment regimen, administered to avoid further clot formation in the lower extremities
thus preventing further embolic episodes
o Unfractionated heparin (UFH) IV or SQ- initial drug of choice
§ Bolus of 80 IU/kg IV and maintenance infusion at 18 IU/kg.
§ Duration is usually 7-10 days (5 days is just as effective
§ Partial thromboplastin time (aPTT) of the patient maintained between 2-3 times the
upper limit of the laboratory normal
o Oral anticoagulation with warfarin - may be started on the first day of heparin therapy (usual
overlap is 3 – 5 days, as full effect of warfarin requires 5 days.)
§ PT should be monitored with an INR target of
• 2.5, with a range of 2.0- 3.0 (1st 3mo)
• 1.5-1.9 – after 3mo
o Low molecular weight heparin (LMWH) e.g. Enoxaparin.
§ 1 mg/kg/SQ q12 hours for up to 3 months in VTE patients with reversible risk factors.
§ For recurrent emboli and nonreversible risk factors, therapy may have to be given
indefinitely.
§ Less bleeding complications from LMWH than UFH
• Thrombolytic Therapy
o Streptokinase, Urokinase, and recombinant Tissue Plasminogen activator (rTPA). Accelerate the
resolution of the pulmonary artery clot and may be used especially in patients with massive
embolism and systemic hypotension.
• Newly-developed Anti-coagulants/Anti-thrombotics
o Most are monotherapeutic
o Specific factor Xa inhibitors e.g. Fondaparinux) in contrast to the LMWH which is
polytherapeutic
• NOAC
o New oral anti-coagulants
o Dabigatran, Rivaroxaban, Apixaban
• Non-pharmacologic
o IVC filter, intermittent pneumatic compression device (IPC), graduated compression stockings
(GCS), and anti- embolic stockings (AES).
Prophylaxis
• UFH – SQ, every 8 hrs; needs aPTT monitoring
• LMWH
o Fondaparinux is a Factor Xa inhibitor, pentasaccharide, given for prophylaxis in medical patients
at 2.5 mg/ subcutaneous q 24hours.
o Rivaroxaban- Factor Xa inhibitor given for prophylaxis in patient who underwent orthopedic
surgery
• Early ambulation, especially for post-operative patients.
• Graduated elastic compression stockings – provide pressure on the lower extremities, to prevent
venous stasis.
• Intermittent pneumatic compression – is a mechanical device attached to the extremities, which
provides some form of passive leg exercises, therefore stimulating muscle contraction
• Inferior vena caval interruption – a most popular and widely used device is the Greenfield filter
JMFV D2017, UST-FMS
18. Hemoptysis p.169, CMDT 2017
Definition
• Hemoptysis is the expectoration of blood in gross amounts or in streaks from a source below the glottis
(Larynx, trachea, bronchi, lungs)
• Massive hemoptysis
o Occurs in 5% of cases is defined as 200-600ml of blood expectoration in 24h
o Clinically, massive hemoptysis is any bleeding that results in impairment of lung function & gas
exchange
o Originates from a bronchial artery in 90% of cases with a 20% fatality rate
Etiology: It can be caused by several factors
• Infections – PTB, paragonimiasis, aspergilloma, amoebic liver abscess (pleuro-pneumonic
complication), necrotizing pneumonias, lung abscess
• Bronchiectasis
• Acute/chronic bronchitis
• Neoplasms – lung malignancies, endobronchial adenoma, carcinoid tumor, choricarcinoma, osteogenic
carcinoma
• Iatrogenic – lung biopsy, catheter-induced, ETT, bronchoscopy
• Trauma – blunt/crushing injuries, penetrating rib fractures
• Cardiovascular conditions – MS, Acute pulmonary edema, aortic aneurysm rupture in a bronchus,
AVMs
• Others: DIC, Anticoagulation, Thrombocytopenia, Aspiration of foreign bodies/gastric contents, Good
Pasture Syndrome, SLE, Wegener’s granulomatosis
• Cryptogenic hemoptysis – 20% of cases where the cause remains unknown despite extensive
evaluation
Pathogenesis
• The lungs are supplied with a dual circulation.
o The pulmonary arteries arise from the right ventricle to supply the pulmonary parenchyma in a
low-pressure circuit.
o The bronchial arteries arise from the aorta or intercostal arteries and carry blood under
systemic pressure to the airways, blood vessels, hila, and visceral pleura.
• Although the bronchial circulation represents only 1-2% of the total pulmonary blood flow, it can
increase dramatically under conditions of chronic inflammation- eg, chronic bronchiectasis-and is
frequently the source of hemoptysis.
Clinical Manifestations
Clinical manifestations depend on the primary disease, site, degree, and rate of hemorrhage.
• Minor hemoptysis may present with just blood streaked sputum, with or without discomfort or
bubbling sensation over the chest.
• Massive hemoptysis, defined as expectoration of 200 to 600 ml of blood over 24 hours may present
with signs and symptoms of asphyxiation and hemodynamic alterations: Tachypnea, dyspnea, ronchi,
Pallor, hypotension, small and rapid pulse
Laboratories/Ancillaries
• Work-up includes a complete otorhinolaryngeal examination with rhinoscopy and nasopharyngeal and
laryngeal endoscopy, to rule out any upper airway sources of bleeding.
• A chest X-ray may be requested to determine whether a pulmonary pathology is the most likely cause.
• AFB and gram staining of sputum are also indicated to search for the root cause of hemoptysis.
• ABG: assess oxygenation, ventilation and acid-base status
Management
• The initial goal of management of massive hemoptysis is therapeutic, not diagnostic.
• Priorities
o The airway should be protected with endotracheal intubation if needed
o Ventilation must be ensured
o And effective circulation must be maintained
• Stop the bleeding
• MILD
o Avoid strenuous activities
o Chest percussion and physiotherapy
o Diagnostic bronchoscopy: control bleeding
• The mechanism by which such factors worsen thyrotoxicosis may be related to cytokine release &
acute immunologic disturbance caused by the precipitating condition leading to thyroid hyperactivity
• Use of salicylates: increases free thyroid hormone levels
Clinical Manifestations
• Clinical manifestations are similar to those of thyrotoxicosis but more exaggerated
• Fever, cardiac findings such as tachycardia out of proportion to fever, mental status changes,
gastrointestinal symptoms such as diarrhea, abdominal pain, generalized weakness, palmar erythema,
tremors, profuse sweating
• Arrythmias accompanied by pulmonary edema or CHF
• Coma & death in 20% of patients
Diagnosis
• The total serum thyroid hormone levels in crisis are not appreciably greater than those in
uncomplicated thyrotoxicosis therefore, Thyroid storm is a clinical diagnosis
o Free hormone is elevated as compared to the bound hormones
• Scoring criteria is confusing & often not very important since treatment is the same once suspected.
Scoring maybe useful in monitoring treatment response
o Grading: Burch & Wartofsky’s Criteria
§ <25 – Storm unlikely
§ 25-44 – Impending storm
§ >45 – Highly Suggestive of storm
o Temperature, CNS effects, GI-hepatic dysfunction, CV dysfunction, heart failure & precipitant
history
• Electrolytes, BUN, blood sugar, liver FTs, plasma cortisol should be monitored
• Diagnosis is incomplete until a search for the trigger has been made
JMFV D2017, UST-FMS
Treatment
• Inhibition of thyroid hormone synthesis & secretion
o Propylthiouracyl
§ A thionamide which inhibit synthesis of thyroid hormones. Used only in 3 situations: 1st
trimester of pregnancy Methimazole allergy, Thyroid storm
§ Loading: 500mg-1g/IV then: 250mg q4
o SSKI (Lugol’s solution)
§ Inhibits the release of thyroid hormones by inducing the Wolff-Chaikoff Effect (high
amounts of iodine would shut down the hyperfunctioning thyroid gland inducing a state
of transient hyperthyroidism)
§ 5 drops q6 (8-10 drops q8)
§ Give 1-2h after PTU
• Sympathetic blockade
o Propanolol
§ Primarily a b-Blocker used in thyroid storm for its Anti-adrenergic properties.
§ 60-80mg q4-6h
• Prevent peripheral conversion of T4 à T3
o Minimal effect of PTU & Propanolol
o Hydrocortisone
§ Glucocorticoid with anti-inflammatory effects used in Thyroid storm to prevent
peripheral conversion of T4 à T3
§ Loading: 300mg/IV Then: 100mg q4
§ Treatment with glucocorticoids is a standard practice because of the possibility of
relative adrenal insufficiency
• Supportive therapy
o IVF – depending on indication, NSS/LRS for volume expansion
o Temperature control – cooling blankets, paracetamol (Aspirin is contraindicated because it may
increase free thyroid hormone)
o Oxygen if required
o Digitalis for CHF & to slow ventricular response
o Sedation & nutrition
o Manage the precipitating event
Active Immunization Products
• Rabies vaccine to induce production of antibodies against the microorganism
• Types
o Purified Vero Cell Rabies Vaccine (PVRV) [0.5 ml]
o Purified Chick Embryo Cell Vaccine (PCECV) [1.0 ml]
• Intramuscular sites of administration
o Adults: deltoid area of each arm
o Infants: anterolateral aspect of the thigh
o NEVER in the gluteal area because absorption is unpredictable
• Standard Intramuscular Schedule (1-1-1-1-1): D0-D3-D7 +/- D14-D28/30
• Pre-exposure Prophylaxis (D0-D7-D21/28) is recommended for individuals at high risk of exposure:
laboratory workers, veterinarians, animal-control personnel, health workers handling rabies cases
Passive Immunization
• Given to provide immediate neutralizing antibodies to cover the gap until the appearance of vaccine
detectable antibodies
• Total computed RIG should be infiltrated around and into the wound as much as anatomically feasible
even if the lesion has healed
• Remaining RIG should be administered deep IM at a site distant from the site of vaccine injection
• Types:
o Human Rabies Immune Globuline (HRIG) – from plasma of human donors; Dose = 20 IU/kg
o Highly Purified Antibody Antigen Binding Fragments (F(ab’)2) – from equine rabies immune
globuline (ERIG); Dose = 40 IU/kg
o Equine Rabies Immune Globulin – from horse serum; Dose = 40 IU/kg
• Ectopic Pregnancy
o Pregnancy that implants outside the uterine cavity with the fallopian tubes being the most
common site of ectopic implantation
o Manifestations: Bleeding with unilateral abdominal pain, history of PID, anemia, cervical
wiggling tenderness & a palpable adnexal mass, US visualization of an adnexal gestational sac
o Management
§ Cross-match blood and arrange for immediate laparotomy
§ Inspect both ovaries & fallopian tubes intraoperatively
• Extensive damage to the tube à salpingectomy (surgical removal of the
fallopian tube)
• Little damage to the tube which rarely happens à salpingostomy (surgical
unblocking of a blocked fallopian tube)
JMFV D2017, UST-FMS
• Hydatidiform Mole
o Characterized by an abnormal proliferation of chorionic villi
o Manifestations: Painless bleeding, early elevation in BP, passage of grape-like cystic structures
per vagina, boggy uterus which is large of AOG, US visualization of multiple cystic structures
within the uterine cavity, abnormally high b-HCG titer
o Management: Evacuate the uterus
§ Vacuum aspiration/suction curettage: lesser risk of uterine rupture, less blood loss,
lower chance of embolizing the abnormal chorionic villi into the systemic circulation
§ Infuse 20u Oxytocin in 1L of fluids to prevent post-evacuation hemorrhage
§ Follow-up with serial HCG measurements q8weeks for 1 year to evaluate the risk for
development of choriocarcinoma
Bleeding in the 2nd half of pregnancy
• Is one which occurs after the 20th week of gestation
• Again, when a gravida in the 2nd half of pregnancy presents at the ED, institute general measures to
stabilize the patient before diagnostic search
o Perform a rapid evaluation of the general condition, do NOT perform vaginal examination at
this stage as placenta previa is a possibility and IE may cause severe hemorrhage
o If in shock, manage appropriately
o If not and vital signs are stable, bleeding is not alarming an Ultrasound should be performed
• Bleeding in this stage may be caused by
o Placenta Previa
o Abruptio Placenta
o Ruptured Uterus
• Placenta Previa
o Implantation of the placenta in the lower uterine segment, which is incapable of generating
active uterine contractions
o Risk factors include previous CS & Multiparity
o Classically presents as PAINLESS bleeding, usually near the end of the 2nd trimester or later
which may be precipitated by intercourse, relaxed uterus, fetal condition may be normal if the
bleeding is not massive
o Management includes volume resuscitation via IV Infusion of NSS/LRS
§ Immediate delivery regardless of AOG if bleeding is profuse & continuous
§ Expectant management if bleeding is light & fetus is still immature
• Keep the patient in the hospital until delivery
• Correct the anemia with FeSO4
• Ensure blood is available for transfusion
§ Indications for delivery
• Mature fetus, dead fetus, fetus with anomaly incompatible with life, mother’s
life is at risk because of excessive blood loss
o Ultrasound – localizes the placenta & confirms the diagnosis
o If unavailable, perform IE under double set-up – be prepared for either vaginal or CS delivery
• Abruptio Placenta
o Premature separation of the normally implanted placenta
o Risk factors: HTN, cigarette smoking, trauma
o Classically presents as PAINFUL uterine bleeding associated with tetanic uterine contractions
and increased baseline uterine pressure, fetal distress (Abnormal FHR pattern)
o Management
§ Rule out coagulopathy by bedside clotting test: failure to clot in 7min = coagulopathy
then treat accordingly
§ Transfuse as necessary, preferably with fresh blood
§ If bleeding is heavy, delivery immediately
§ If bleeding is light to moderate, the course of action depends on the FHT
• Normal FHT, poor contractions à augment labor
• Abnormal FHT à rapid vaginal delivery or timely CS delivery
• Ruptured Uterus
o Shock, tender abdominal distention, easily palpable fetal parts, abnormal uterine contour
o Risk factors: labor induction/augmentation, previous CS
o Bleeding may occur vaginally unless the fetal head is blocking the pelvis
o Management
§ Fluid resuscitation or blood transfusion as necessary prior to surgery
JMFV D2017, UST-FMS
§ Immediate CS delivery
§ Repair the uterus if surgically possible, if not à hysterectomy
Post-partum Hemorrhage
• Any blood loss that results in signs and symptoms of hemodynamic instability in the post-partum
period
o PRIMARY PPH: occurs within 24 hours after delivery
o SECONDARY PPH: occurs after 24 hours to 6 weeks after delivery
o > 500mL for NSD
o > 1L for cesarean section
• Etiology: 4T’s
o Again, general measures should be instituted first prior to diagnostic search, manage shock
appropriately then asses the 4Ts of PPH
• Tone (Uterine tone)
o Uterine atony from Rapid or prolonged labor, overdistended uterus
§ Immediate-onset bleeding of dark blood
§ Relaxed uterus
o Massage the uterus to allow adequate contraction
o Give uterotonic drugs: Oxytocin, Methylergonovine
o If bleeding persists,
§ Perform bimanual compression of the uterus
§ Compress the abdominal aorta
§ Surgery if necessary: vessel ligation, laparotomy or hysterectomy
• Trauma (Lacerations & Uterine rupture)
o Tears/lacerations of the cervix, vagina, or perineum
§ May be due to precipitate delivery, macrosomia, assisted vaginal delivery
§ Uterus is well-contracted & there is passage of fresh blood
o Examine vagina, vulva, perineum & cervix for tears and lacerations
o 1st & 2nd degree lacerations à apply pressure, if bleeding persists à suture
o 3rd & 4th degree lacerations à suture
• Tissue (Retained placental fragments, abnormal placentation)
o Inspect placenta for completeness, explore uterus & evacuate. Give uterotonics
• Thrombin (Coagulation defects)
o Treat according to particular defect
Pathogenesis
• Normally: Trophoblastic invasion is characterized by extensive remodeling of the spiral arterioles
within the decidua basalis. Endovascular trophoblasts replace the vascular endothelial and muscular
linings to enlarge the vessel diameter
• In preeclampsia, there is incomplete trophoblastic invasion. With this, decidual vessels, but not
myometrial vessels, become lined with endovascular trophoblasts. The deeper myometrial arterioles
do not lose their endothelial lining and musculoelastic tissue, giving rise to narrow-caliber vessels. This
leads to impairment in placental blood flow & placental necrosis
• Diminished perfusion and a hypoxic environment eventually lead to release of placental debris or
microparticles that incite a systemic inflammatory response
• This equates to maternal endothelial dysfunction & activation leading to
o Systemic vasospasm
§ Hypertension
§ Seizures
§ Oliguria
§ Liver ischemia
o Capillary leak
§ Edema
§ Proteinura
§ Hemoconcentration
o Activation of Coagulation
§ Thrombocytopenia
JMFV D2017, UST-FMS
Clinical Manifestations
Preeclampsia without severe features Preeclampsia with severe features
SBP ≥ 140 or DBP ≥ 90, on 2 occasions at least 4 SBP >160 or DBP >110 on 2 occasions at least 4 hours
hours apart apart while the patient is on bed rest
Diagnosed after 20 weeks AOG Thrombocytopenia (platelet count <100,000/microliter)
(+) Proteinuria 0.3g or 300 mg or more in a 24-hr AST or ALT elevated to >2x the upper limit of normal
urine specimen Oliguria <400cc/day
Proteinuria > 2g/24hrs or +2 on urine dipstick
Serum creatinine > 1.2 mg/dL or a doubling of the
serum creatinine concentration in the absence of other
renal disease
Pulmonary edema
New-onset persistent headache or visual disturbances
Management
• Goals of treatment
o Prevention of convulsions
o Control hypertension
o Delivery at an optimum time and mode
• Magnesium sulfate
o Anticonvulsant of choice: prevents eclampsia by reducing cerebral vasoconstriction and
ischemia
o Loading dose: 4 g/SIVP over 20 minutes then 5 g/deep IM on each buttocks
o Maintenance dose: 5 g/deep IM on each buttocks q6 hours
o Serum therapeutic level: 4-7mEq/L (narrow therapeutic index) so monitor:
§ DTRs must be ++
§ RR must be >12cpm
§ UO of at least 25-30cc/h
o Toxicity
§ 10 mEq/L: loss of patellar rellex
§ 12 mEq/L: respiratory depression
§ 15 mEq/L: altered atrioventricular conduction and (further) complete heart block
§ >25 mEq/L: cardiac arrest
§ Treat with calcium gluconate 1g IV
• Nicardipine
o Calcium channel blocker which is safe to control hypertension in pregnant patients
o 10 mg in 90cc D5W to run at 10ugtts/min, titrate at increments/decrements of 5ugtts/min to
maintain BP of MAP – 20% MAP (140-150/90)
o DO NOT decrease BP abruptly AND not below 130/90 mmHg
o WOF: palpitations, tachycardia, headache
• Optimum time & mode of delivery – definitive treatment for preeclampsia is delivery of the fetus &
placenta, this depends on fetal & maternal factors
o AOG > 37 weeks, if far from term but HTN is severe, give Glucocorticoids for fetal lung
maturation
o Severity of disease
o Fetal status
o Maternal condition
o Nursery capabilities
Complications
• IUGR (intrauterine growth restriction)
• Fetal death
• Abruptio placenta
• Maternal cerebral hemorrhage
• Pulmonary edema
JMFV D2017, UST-FMS
33. Gynecologic Emergencies p.281, Katz Comprehensive Gynecology 6e
Pelvic Inflammatory Disease
Definition
• Comprises a spectrum of infections of the female upper reproductive tract including
o Endometritis – inflammation of the endometrium
o Salpingitis – inflammation of the fallopian tubes
o Oophoritis – inflammation of the ovaries
• The main risk factor for pelvic inflammatory disease is having unprotected intercourse with multiple
sexual partners
Etiolopathogenesis
• PID is usually initiated by ascending infections from the lower genital tract (vagina and cervix)
• Neisseria gonorrhoeae and Chlamydia trachomatis are often implicated, although most cases are
polymicrobial in nature involving the vaginal flora (G. vaginalis, Haemophilus influenzae, enteric Gram-
negative rods, and Streptococcus agalactiae)
• Any sexually active female individual is at risk for PID, but those with multiple sexual partners are at
the highest risk.
• PID represents a spectrum of clinical disease, from mild, vague pelvic symptoms to tubo-ovarian
abscess and, rarely, fatal intra-abdominal sepsis. In some women, the inflammatory process can extend
to the liver capsule to cause perihepatitis (the Fitz-Hugh Curtis syndrome)
Clinical Manifestations
• Classic triad:
o Bilateral, dull, vague lower abdominal pain
o Cervical motion tenderness
o Adnexal tenderness
• AUB – presents in 1/3 of women: Post-coital bleeding, Intermenstrual bleeding & menorrhagia
• Fever, Purulent discharge
Diagnosis – mainly clinical but ancillaries may aid in the diagnosis
• CBC: Leukocytosis, ESR & CRP: Elevated, Urinalysis
• TVS to rule out tubo-ovarian abscess
• Laparoscopy – gold standard in the diagnosis of PID
o May determine severity of disease, detects Fitz-Hugh Curtis syndrome & offer opportunity to
perform operative procedures
o Mild: erythema, edema, no spontaneous purulent exudates, tubes freely movable
o Moderate: gross purulent material evident, more marked erythema & edema, tubes may not be
freely movable, fimbria stroma may not be patent
o Severe: pyosalpinx
• The presumptive clinical diagnosis of PID is made in sexually active young women, especially women at
high risk for sexually transmitted infections (STIs), who present with pelvic or lower abdominal pain
and have evidence of cervical motion, uterine, or adnexal tenderness on exam.
Management
• Treatment is indicated for patients with this presumptive clinical diagnosis of PID, even if findings are
subtle or minimal, since complications (tubal infertility, ectopic pregnancy, chronic pelvic, septic shock)
are more common if treatment is withheld or delayed
• 2 types: Out-patient or In-hospital
• Out-patient Regimen
o Given to patients with mild or moderate PID without indications for admission
o First line:
§ Ceftriaxone 250mg/IM single dose + Doxycycline 100mg PO BID for 14 days
§ + Metronidazole 500mg PO BID for 14 days if with Bacterial Vaginosis
• In-hospital Regimen
o Indications for admission
§ Pregnancy, Lack of response or tolerance to oral medications, Nonadherence to therapy
§ Inability to take oral medications due to nausea and vomiting
§ Severe clinical illness (high fever, nausea, vomiting, severe abdominal pain)
§ Complicated PID with pelvic abscess (including tuboovarian abscess)
§ Possible need for surgical intervention or diagnostic exploration for alternative etiology
(eg, appendicitis)
JMFV D2017, UST-FMS
o Regimen A: Cefoxitin 2g/IV q6 or Cefotetan 2g/IV q12 and Doxycycline 100mg PO q12
§ First line
o Regimen B: Clindamycin 900mg/IV q8 and Gentamycin 2mg/kg loading dose then 1.5mg/kg q8
§ Given to patients with TOA, surgery is needed if TOA is documented for drainage
Profuse Vaginal Bleeding
• Determine the vital signs
• Note for the presence of pallor or impending shock (hypotension, weak pulses, diminishing UO)
• Institute fluid resuscitation
o 2 venous access lines
o Give crystalloids: D5LRS, NSS
• CBC & blood typing: Prepare for blood transfusion if necessary
• Determine the amount of bleeding and localize the source
o Vulva, vagina, cervix, uterus
Management
• Vulvar bleeding
o Traumatic in origin
o Apply pressure dressing to reduce the amount of blood loss
• Bleeding from the vagina coming from the cervical os
o Tumor or neoplastic
o Insert a packing to lessen bleeding
• Uterine bleeding
o IV Estrogen 25mg q2-4h or Oral Estrogen 2.5mg q6 until bleeding stops then taper or shift to an
oral regimen for 30-40days
§ On the last 10 days, add 10nmg OD or 10 days à medical curettage
o OCP 1 tablet QID until bleeding is controlled, taper or shift to oral regimen for 30-40days
o Impending shock: D&C is considered the fastest way to control the bleeding
JMFV D2017, UST-FMS
35. Maxillofacial Injuries p.336, UpToDate Article on Maxillofacial Trauma 2017
Definition/Etiology
• Injuries to the facial region involving soft tissue & facial skeleton resulting from accidental or deliberate
trauma to the face
• The nose, zygoma, and mandible are the most commonly fractured among the facial bones
• Injuries to the mid-face usually results from vehicular accidents with passengers and pedestrians being
more or less equally involved, followed by interpersonal violence
• May be closed or open fractures with incidence being almost equal for both
Pathogenesis
• Injuries occur when energy (most often kinetic) transferred to the body exceeds tolerance of the tissue
• The likelihood of injury is related to the amount of energy transferred & the condition of the
underlying tissue
• Traditionally, trauma has been classified as blunt or penetrating, but in many cases the effect is a
combination
Types of Fractures
• Le Fort I – horizontal fracture, above the apices of the teeth; usually have minimal mobility & stable
occlusion
• Le Fort II – pyramidal fractures in the maxilla involving the nasal, lacrimal & ethmoidal bones & the
zygomatico-maxillary sutures
• Le Fort III – high transverse fractures of the maxilla at the base of the nose & ethmoid region,
extending across the orbits to the lateral rim & separating the zygomatico-frontal suture area
Clinical Manifestations
• Periorbital ecchymosis
• Malocclusion & mobility of the mid-face
• Fractures as mentioned above
Diagnosis
• CT Scan or computerized 3D Examination will confirm the diagnosis & help in the planning of
reconstructive surgey
• X-rays of the affected parts may also be helpful
Mandibular Fracture Zygomatic Fracture Facial Soft tissue injuries
In the elderly, the bones become 2nd most common injury to facial Results from either deliberate or
fragile due to atrophy and skeleton: malar bones; two types accidental trauma
resorption of the alveolus. of disruptions:
Condyle is most often fracture 1) Low Velocity Impact: swelling Bleeding is excessive: out of
Treatment: align the mandible in not excessive comminution proportion to the size of
proper occlusion with the (breaking) of bone is rare ie. external injury
opposing maxilla Punch/fall
2) High Velocity Impact: swelling is
marked, comminution (breaking)
common ie. MVA
Management
• The immediate priority is the establishment & preservation of airway, control of bleeding
• Remove any obstruction to the airway like blood clots, displaced tongue, loose teeth, bone fragments,
broken dentures, and foreign bodies
• Do not allow the patient to lie flat on their back to avoid aspiration & to prevent their tongue from
falling back on their airway
• Intubation – may be indicated to maintain the airway
• Analgesics (Morphine, strong narcotics are contraindicated because it decreases respiration which
masks signs of head injury)
• Le Fort II or III: CSF rhinorrhea → antibiotic therapy
• Internal skeleton fixation by external rod and cheek wires → immobilize the maxilla
JMFV D2017, UST-FMS
Management
At the scene of the accident
• Perform primary survey & secure the airway, breathing & circulation
• Halt the burning process by removing the patient from the scene of the fire, remove burning clothes
• Apply cold compress: Tap water > cold water
• Irrigate chemical burns with liberal amounts of water, do not neutralize the chemical agent as this may
release more heat worsen the injury
• Cover the patient with clean sheets to protect the wound
• Transfer to the ER
At the ER
• Make a quick estimate of the extent of the injury, fill-out burn chart & record
• Elicit history of the incident. Note the possibility of smoke inhalation, associated injuries, pertinent
medical history
• Determine if the patient needs hospitalization or treat in the OPD
• Indications for admission
o Partial thickness burns >10% BSA
o Involvement of face, neck, both hands, both feet, perineum
o 3rd degree burns in all age groups
o Electrical (contact) and chemical burns
o Associated injuries: soft tissue trauma, fractures, smoke inhalation, head injury
o Complicating medical problems: diabetes mellitus, pulmonary disease, peptic ulcer
o Suspected child abuse or neglect / self inflicted / psychological problems
• Out-patient Care
o Burns & Injury: cold compress; clean wound with soap and water; debride dead tissue (blisters
2-3cm may be left intact); local antibiotics can be used with wound dressings and systemic
antibiotics are not required.
o Thermal Burns: topical antimicrobials can be given (silver sulfadiazine (silvadene), calcium
nitrate – silver sulfadiazine, povidione-iodine, nitrofurazone, chlorhexidine gluconate,
gentamicin); overtreatment is the most common cause of complications → so petroleum jelly
or non-adherent porous dressings are sufficient except when the burn is grossly contaminated
o Thermal Injury: Tetanus prophylaxis should be administered; if a patient has no tetanus
immunization history give 250units of tetanus human globulin or 3,000 units of anti-tetanus
serum (ATS). Booster dose of tetanus toxoid should be given if the patient had not been
boostered for the last 5 years.
o Oral analgesics can be given for pain relief
In the hospital (admitted patients)
• Volume replacement via Parkland’s Formula
o PLRS is used
o 4cc PLRS x kg Body Weight x %TBSA
o 1⁄2 administered over the 1st 8 hours post-injury
o 1⁄2 administered over the next 16 hours post injury
o Titrate fluid to urine output
§ Adults: 30cc/hour
§ 100 cc/hour for electrical burns
§ Children: 1 cc/kg/hour
• Wound management
o Exposure Therapy (Open Dressing): superficial burn wounds involving the face and
perineum → light and cool environments without topical antibiotics after debridement
o Occlusive Dressing (Close method): for circumferential burns and those requiring transport
w/ or w/o topical antibiotics
o Excisional Therapy: most demanding procedure where all non-viable tissues are removed
followed by immediate wound coverage (either temporary or permanent – done between
the 2nd and 5th post burn days)
o Laser Doppler Velocrimetry (LDV): most promising in detecting burn depth; measures the
degree of blood flow within and surrounding burned tissues
o Escharotomy / Fasciotomy: circumferential and constricting burns
o Escharotomy: only if skin and subcutaneous tissue are constricting
o Fasciotomy: deep compartment hypertension
o Skin Grafting: remains unhealed by the end of the 4th week
JMFV D2017, UST-FMS
40. Acute Urinary Retention p.298, Tintinalli’s Emergency Medicine 8E
Definition
• Acute urinary retention is a painful urologic emergency characterized by a sudden inability to empty
the urinary bladder
• Though it can occur at all ages and gender, it usually occurs in elderly males with benign prostatic
hyperplasia
Pathogenesis
• Normally (you can choose not to say this)
o The voiding process or micturition involves the complex integration and coordination of high
cortical neurologic functions (Sympathetic, parasympathetic, somatic) and Muscular functions
(detrusor and sphincter smooth muscle)
o As the sensory impulse of bladder distention transmits to cortical centers, these areas of the
brain smoothly coordinate voluntary urination
o Continent urine storage in the bladder requires both relaxation of the detrusor muscle (through
β-adrenergic stimulation and parasympathetic inhibition) and contraction of the bladder neck
and internal sphincter (through α-adrenergic stimulation)
o The contraction of bladder detrusor muscle (by cholinergic muscarinic receptors) and relaxation
of both the internal sphincter of bladder neck and the urethral sphincter (through α-adrenergic
inhibition) contribute to smooth urination
• Anything that causes interference with the neurologic & muscular control of the voiding process can
result in voiding dysfunction, hence urinary retention
Etiology: The causes generally fall under 2 categories: Obstructive: Bladder outlet obstruction & Myogenic:
Bladder muscle failure
• Obstructive causes
o Penis: Phimosis (foreskin can not be retracted), meatal stenosis, foreign body constriction (rings
& rubber bands)
o Urethra: tumors, foreign bodies, calculi, hematoma
o Prostate gland: BPH, carcinoma, severe prostatitis, bladder neck contracture, prostatic
infarction
• Myogenic causes
o Neurologic: Motor paralysis, spinal shock, spinal cord syndrome, tabes dorsalis, diabetes,
multiple sclerosis, syringomyelia, herpes zoster
o Drugs: Antihistamines, anticholinergics (ie. Atropine, phenothiazines, diazepam, NSAIDs),
antispasmodics, tricyclic antidepressants, α-adrenergic stimulators /β-agonists (ie.
Isoproterenol, terbutaline)
o Psychogenic: Acute anxiety
o Traumatic: Urethral/bladder injury
Clinical Manifestations
• History
o Elderly patients with progressive decrease in the force & caliber of the urinary stream
o Nocturia, dribbling, prior history of retention, prior catheterization, dilatation or prostatectomy
o Bone pain & weight loss could be manifestations of malignancy
o Incontinence is a paradoxical manifestation: overflow of a markedly distended bladder
• PE
o Distended bladder: prominent hypogastrium
o Slight pressure will cause tremendous discomfort
o In fat individuals, percussion will reveal a dull sound of distended bladder
• AUR may be an ominous sign of a more serious underlying condition such as a Cerebrovascular
accident, TIA, malignancy & DKA
Diagnosis
• Diagnosis can be established clinically by history & physical exam
• But Bedside Ultrasound can easily identify urinary retention
• CBC, Urinalysis/urine culture to identify infection (once urine is obtained)
• Prolonged obstruction may result in impaired renal function and electrolyte imbalance, so obtain renal
function studies (BUN/sCr) and serum electrolytes
JMFV D2017, UST-FMS
Management
They Immediate goal is to empty & decompress the urinary bladder
• Initially, perform Urethral catheterization
o French 16 or 18 foley catheter + xylocaine jelly
§ To lubricate thus preventing involuntary contraction of the pelvic muscles
§ To ease the pain of catheterization
o If this fails,
• Decompress the bladder via suprapubic catheterization
o Identify the symphysis pubis à then mark the point about 1cm above the SP
o Inject xylocaine jelly
o Nick with a stab knife & puncture straight posteriorly
o A sudden give indicates you are in the bladder
• Keep the catheter in place as indwelling
• Immediate referral is the rule (urology, neurology)